[Clinical significance of the measurement of serum cytokeratin-18 in patients with non-alcoholic steatohepatitis].

Tsuneo Watanabe, Masao Takemura, Kuniaki Saito, Hiroyasu Ito, Takayuki Hattori, Ayako Sekine, Kinya Yamada, Tomohiro Kato, Eiichi Tomita, Toshio Matsuoka, Mitsuru Seishima

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Epidemiologic data suggest that non-alcoholic fatty liver disease (NAFLD) have an increased tendency to occur in patients who are associated with metabolic conditions such as obesity, type 2 diabetes mellitus, and dyslipidemia. NAFLD represents a wide spectrum of conditions ranging from fatty liver, which in general follows a benign, no-progressive clinical course, to non-alcoholic steatohepatitis (NASH), a more serious form of NAFLD that may progress to cirrhosis and end stage liver disease. However, currently the diagnosis of NASH requires an invasive liver biopsy. The aim of this study is to evaluate whether Cytokeratin 18 (CK-18) has potential non-invasive diagnostic capability for the NASH. Serum levels of alanine aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase, adiponectin, leptin, and CK-18 were measured in 27 patients (8 patients with simple fatty liver, 6 fatty liver with fibrosis patients, 13 patients with NASH) and 23 healthy controls. Regarding gender difference in the control group, although both adiponectin and leptin significantly increased in the female compared with the male (p < 0.002 and p < 0.01, respectively), there were no significant gender differences in CK-18. For the conventional liver function tests, there were no significant differences in 4 groups. Serum levels of adiponectin was significantly lower in patients with NASH compared with the control group(p < 0.001), and both leptin and CK-18 were markedly higher in patients with NASH compared with control group (p < 0.001). These results suggested that measurement of serum CK-18 is useful for assessing the NASH.

Original languageEnglish
Pages (from-to)19-24
Number of pages6
JournalUnknown Journal
Volume61
Issue number1
Publication statusPublished - 01-01-2013
Externally publishedYes

Fingerprint

Keratin-18
Fatty Liver
Serum
Adiponectin
Leptin
Control Groups
End Stage Liver Disease
gamma-Glutamyltransferase
Liver Function Tests
Dyslipidemias
Alanine Transaminase
Liver Cirrhosis
Type 2 Diabetes Mellitus
Alkaline Phosphatase
Fibrosis
Obesity

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Watanabe, T., Takemura, M., Saito, K., Ito, H., Hattori, T., Sekine, A., ... Seishima, M. (2013). [Clinical significance of the measurement of serum cytokeratin-18 in patients with non-alcoholic steatohepatitis]. Unknown Journal, 61(1), 19-24.
Watanabe, Tsuneo ; Takemura, Masao ; Saito, Kuniaki ; Ito, Hiroyasu ; Hattori, Takayuki ; Sekine, Ayako ; Yamada, Kinya ; Kato, Tomohiro ; Tomita, Eiichi ; Matsuoka, Toshio ; Seishima, Mitsuru. / [Clinical significance of the measurement of serum cytokeratin-18 in patients with non-alcoholic steatohepatitis]. In: Unknown Journal. 2013 ; Vol. 61, No. 1. pp. 19-24.
@article{04736890312a4ff79627c07b44e29366,
title = "[Clinical significance of the measurement of serum cytokeratin-18 in patients with non-alcoholic steatohepatitis].",
abstract = "Epidemiologic data suggest that non-alcoholic fatty liver disease (NAFLD) have an increased tendency to occur in patients who are associated with metabolic conditions such as obesity, type 2 diabetes mellitus, and dyslipidemia. NAFLD represents a wide spectrum of conditions ranging from fatty liver, which in general follows a benign, no-progressive clinical course, to non-alcoholic steatohepatitis (NASH), a more serious form of NAFLD that may progress to cirrhosis and end stage liver disease. However, currently the diagnosis of NASH requires an invasive liver biopsy. The aim of this study is to evaluate whether Cytokeratin 18 (CK-18) has potential non-invasive diagnostic capability for the NASH. Serum levels of alanine aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase, adiponectin, leptin, and CK-18 were measured in 27 patients (8 patients with simple fatty liver, 6 fatty liver with fibrosis patients, 13 patients with NASH) and 23 healthy controls. Regarding gender difference in the control group, although both adiponectin and leptin significantly increased in the female compared with the male (p < 0.002 and p < 0.01, respectively), there were no significant gender differences in CK-18. For the conventional liver function tests, there were no significant differences in 4 groups. Serum levels of adiponectin was significantly lower in patients with NASH compared with the control group(p < 0.001), and both leptin and CK-18 were markedly higher in patients with NASH compared with control group (p < 0.001). These results suggested that measurement of serum CK-18 is useful for assessing the NASH.",
author = "Tsuneo Watanabe and Masao Takemura and Kuniaki Saito and Hiroyasu Ito and Takayuki Hattori and Ayako Sekine and Kinya Yamada and Tomohiro Kato and Eiichi Tomita and Toshio Matsuoka and Mitsuru Seishima",
year = "2013",
month = "1",
day = "1",
language = "English",
volume = "61",
pages = "19--24",
journal = "Unknown Journal",
number = "1",

}

Watanabe, T, Takemura, M, Saito, K, Ito, H, Hattori, T, Sekine, A, Yamada, K, Kato, T, Tomita, E, Matsuoka, T & Seishima, M 2013, '[Clinical significance of the measurement of serum cytokeratin-18 in patients with non-alcoholic steatohepatitis].', Unknown Journal, vol. 61, no. 1, pp. 19-24.

[Clinical significance of the measurement of serum cytokeratin-18 in patients with non-alcoholic steatohepatitis]. / Watanabe, Tsuneo; Takemura, Masao; Saito, Kuniaki; Ito, Hiroyasu; Hattori, Takayuki; Sekine, Ayako; Yamada, Kinya; Kato, Tomohiro; Tomita, Eiichi; Matsuoka, Toshio; Seishima, Mitsuru.

In: Unknown Journal, Vol. 61, No. 1, 01.01.2013, p. 19-24.

Research output: Contribution to journalArticle

TY - JOUR

T1 - [Clinical significance of the measurement of serum cytokeratin-18 in patients with non-alcoholic steatohepatitis].

AU - Watanabe, Tsuneo

AU - Takemura, Masao

AU - Saito, Kuniaki

AU - Ito, Hiroyasu

AU - Hattori, Takayuki

AU - Sekine, Ayako

AU - Yamada, Kinya

AU - Kato, Tomohiro

AU - Tomita, Eiichi

AU - Matsuoka, Toshio

AU - Seishima, Mitsuru

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Epidemiologic data suggest that non-alcoholic fatty liver disease (NAFLD) have an increased tendency to occur in patients who are associated with metabolic conditions such as obesity, type 2 diabetes mellitus, and dyslipidemia. NAFLD represents a wide spectrum of conditions ranging from fatty liver, which in general follows a benign, no-progressive clinical course, to non-alcoholic steatohepatitis (NASH), a more serious form of NAFLD that may progress to cirrhosis and end stage liver disease. However, currently the diagnosis of NASH requires an invasive liver biopsy. The aim of this study is to evaluate whether Cytokeratin 18 (CK-18) has potential non-invasive diagnostic capability for the NASH. Serum levels of alanine aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase, adiponectin, leptin, and CK-18 were measured in 27 patients (8 patients with simple fatty liver, 6 fatty liver with fibrosis patients, 13 patients with NASH) and 23 healthy controls. Regarding gender difference in the control group, although both adiponectin and leptin significantly increased in the female compared with the male (p < 0.002 and p < 0.01, respectively), there were no significant gender differences in CK-18. For the conventional liver function tests, there were no significant differences in 4 groups. Serum levels of adiponectin was significantly lower in patients with NASH compared with the control group(p < 0.001), and both leptin and CK-18 were markedly higher in patients with NASH compared with control group (p < 0.001). These results suggested that measurement of serum CK-18 is useful for assessing the NASH.

AB - Epidemiologic data suggest that non-alcoholic fatty liver disease (NAFLD) have an increased tendency to occur in patients who are associated with metabolic conditions such as obesity, type 2 diabetes mellitus, and dyslipidemia. NAFLD represents a wide spectrum of conditions ranging from fatty liver, which in general follows a benign, no-progressive clinical course, to non-alcoholic steatohepatitis (NASH), a more serious form of NAFLD that may progress to cirrhosis and end stage liver disease. However, currently the diagnosis of NASH requires an invasive liver biopsy. The aim of this study is to evaluate whether Cytokeratin 18 (CK-18) has potential non-invasive diagnostic capability for the NASH. Serum levels of alanine aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase, adiponectin, leptin, and CK-18 were measured in 27 patients (8 patients with simple fatty liver, 6 fatty liver with fibrosis patients, 13 patients with NASH) and 23 healthy controls. Regarding gender difference in the control group, although both adiponectin and leptin significantly increased in the female compared with the male (p < 0.002 and p < 0.01, respectively), there were no significant gender differences in CK-18. For the conventional liver function tests, there were no significant differences in 4 groups. Serum levels of adiponectin was significantly lower in patients with NASH compared with the control group(p < 0.001), and both leptin and CK-18 were markedly higher in patients with NASH compared with control group (p < 0.001). These results suggested that measurement of serum CK-18 is useful for assessing the NASH.

UR - http://www.scopus.com/inward/record.url?scp=84881230877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881230877&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 19

EP - 24

JO - Unknown Journal

JF - Unknown Journal

IS - 1

ER -